Authors: Alexi, T Borlongan, CV Faull, RLM Williams, CE Clark, RG Gluckman, PD Hughes, PE

Citation: T. Alexi et al., Neuroprotective strategies for basal ganglia degeneration: Parkinson's andHuntington's diseases, PROG NEUROB, 60(5), 2000, pp. 409-470

Authors: Alexi, T Faull, RLM Hughes, PE

Citation: T. Alexi et al., Variable susceptibility to neurotoxicity of systemic 5-nitropropionic acid, CONT NEUROS, 2000, pp. 129-140

Authors: Hughes, PE Alexi, T Williams, CE Clark, RG Gluckman, PD

Citation: Pe. Hughes et al., Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease, NEUROSCIENC, 92(1), 1999, pp. 197-209

Authors: Hughes, PE Alexi, T Walton, M Williams, CE Dragunow, M Clark, RG Gluckman, PD

Citation: Pe. Hughes et al., Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system, PROG NEUROB, 57(4), 1999, pp. 421-450

Authors: Alexi, T Hughes, PE van Roon-Mom, WMC Faull, RLM Williams, CE Clark, RG Gluckman, PD

Citation: T. Alexi et al., The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease, EXP NEUROL, 159(1), 1999, pp. 84-97